

1/10/2017	11:00am	The Use of Complementary and Integrative Health in the OEF/OIF/OND Veteran Population	Spotlight on Pain Management	Herman, Patricia Lorenz, Karl Taylor, Stephanie
2/7/2017	11:00am	Integrative Management of Centrally Amplified Pain using Autonomic Self-Regulation	<u>Spotlight on</u> <u>Pain</u> Management	Ginsberg, Jay "Jack"
2/15/2017	2:00pm	The Cost-Effectiveness of Complementary and Alternative Treatments to Reduce Pain	HERC Health Economics Seminar	Herman, Patricia Lorenz, Karl Taylor, Stephanie
3/7/2017	11:00am	Non-Pharmacological Approaches to Chronic Musculoskeletal Pain Management: Recommendations from the State-Of-The-Art conference	Spotlight on Pain Management	Kerns, Robert Krebs, Erin

VHA Pain Management Program, Pain Research Working Group Pain Research, Informatics, Multimorbidities and Education (PRIME) Center Robert D. Kerns, Ph.D., Director and Special Advisor for Pain Research Robin M. Masheb, Ph.D., Director of Education, PRIME Center VA Connecticut Healthcare System and Dept of Psychiatry, Yale University SoM

# JP (Jack) Ginsberg, PhD

Licensed Clinical Psychologist/Neuropsychologist and Principal Investigator, **Dorn VA Medical Center Basic Science Research Assistant Professor** University of South Carolina, School of Medicine, **Dept of Pharmacology, Physiology & Neuroscience** Columbia, SC jay.ginsberg@va.gov 803.776.4000 x6644


# **Disclaimer and Disclosure**

- Clinical Neuropsychologist
  - Interested in Cognitive Psychophysiology
  - MH clinical research and hypothesis testing of interventions for symptom reduction
    - Emotional self-regulation and cognitive appraisal
  - Not expert in cardiology, autonomics, or pain
- Slides are original or freely available from internet with acknowledgment
- Planned for 45-50 minutes and questions
- No conflicts of interest, affiliations, or product endorsements


## <u>Overview</u>


- 1. Autonomic Self-Regulation (ASR)
  - a. Heart rate variability (HRV)
  - b. HRV Biofeedback (HRVB)
    - i. Coherence
    - ii. Mindfulness
- 2. Pain and Centrally Sensitized Chronic Pain
  - a. Stress and Chronic Pain as Stressor
- 3. Model of ASR and Centrally Sensitized Pain
- 4. Research on ASR and Centrally Sensitized Chronic Pain







• R-R or N-N










HRV is an indicator of autonomic function. Variability is equal to variance, which is maximized when beat-to-beat intervals increase and decrease in a smooth rhythm, one that approximates a sine wave. A smooth sinusoidal rhythm of ibi's is characteristic of a healthy heart under resting conditions; the amount of variability is directly related to respiration rate, and many inter-individual factors such as age, gender, height, and fitness level

#### **RR Interval Time Series**




# R-R Tachogram

# RR = interbeat interval (msec)

$\underline{RR} = ibi = msec/beat$	<u>BPM</u>
1333	45
1200	50
1091	55
1000	60
857	70
833	72
800	75
750	80
667	90
600	100
500	120


- ibi (msec) \* BPM = 60,000
- ibi (msec) = 60,000/BPM
- BPM = 60,000/ibi (msec)



# Attaining Coherence: Resonance Frequency Breathing (RFB)


- HRV is related to respiratory cycle
- At ~ 6 breaths/minute
  - HRV and respiratory cycle synchronize
  - HRV is maximized
  - Resonant Frequency Breathing
- 'Coherence'

Note: 6 breaths/min=10 seconds per breath=0.1 Hz)




72 BPM, Max-Min 20 1 cycle/10 sec, 12 beats/cycle 6 cycles (1 minute )

Transformation of a time series to a frequency spectrum is done with the Fourier transform. A frequency spectrum is analyzed in terms of 'power' or area under the curve across a range of frequencies. Power is directly related to variance of the untransformed time series.



The heart rhythm pattern shown in the top graph is characterized by its erratic, irregular pattern (Non-coherence), and associated with negative emotions such as anger or frustration. The bottom graph shows a regular heart rhythm pattern (Coherence), observed when an individual is breathing properly and experiencing sustained, modulated positive emotions such as compassion or gratitude.



13

# **HRV Biofeedback**




# HRV-B participant and coach




# HRV-B coaching essential elements

- Paced breathing at resonant frequency.
- Mindfulness or imagery focused on breathing and the heart. Focused attention on air entering and exiting the chest and passing thorough the heart
- Positive emotional state (PES). Occupy the mind during the HRVB session with thoughts of compassion, gratitude, apreciation, etc.





# <u>Mindfulness for Pain: books, cd's,</u> <u>online courses, ceu's</u>



# Mindfulness Defined

## "Moment-to-moment non-judgmental awareness"

## Mindfulness in Practice

- Body Scanning
  - Lying on back
  - Quiet
  - Focus attention on organs
- Mindfulness (meditation)
  - Secular
- Yoga postures

# Effects of Mindfulness

- Improves quality of life
- No evidence that Mindfulness prevents or cures disease
  - Not recommended to lower blood pressure

### Exploring the Promise of Mindfulness as Medicine

Laura Ruchholg

A new frontier in treatment for mental-linesses and other chronic con drifters may not come from pharmaconneal companies, but from within, as mintfulness practices gain traction.

Mindfuliess procilies as we know them torky a proposed in 2500-year-old Buchhist matitation practices and are often deschoed as "....caying attention to the presortmomer/lexter process/th/opennoss, turiosity, and a will regress to be with what let (http://inarcuclaundu/). Herbert Armson, MO, Iounder of the Herbert-Herby matitude for Mind Eddy Markone at Musechargetts General Hospital is often and task with bringing mindfulness into the reaction of Westennies during the History 5000 (*The Selayotion Response* outlined techniques, occambat the harmful efforts of screas with relaxation methods similar to mechation.

These process didn't stay ladged in the 1970s file a macrathé paint holder, how ever, Scorral structured montfulness prugrans have since Lean provoloced and an using implemented in clinical practice. One of these is minifulness pained stress requetion (MESK), ploneered by fon Kabat-Zinn, PhD, MPH, rounding even five directure of the Contention Minifolmess in Medicine, leach Contention Minifolmess in Medicine, leach Contentor Minifolmess in Medicine, leach Contentor Medice School (http://) usa .pow/ K2m80F).

Another is mindfulness based cognitive biening (MBCD, a blend of MRSR and Cognitive-linhavioral therbuy established by Zindel Segal, Hhill, a cognitive psychologist stitle University of Toronto, along with colleagues Maric Williams, PhD, and John Teacdae, PhD (http://lusa.gov/teOvpCo)

According to Gregory Levis Filterhione. MD, director of the Benson-Henry Institute, "---minofulness and other meditative technologies can provide adjunctive benefits for both and that including mental health."


But Fricohione Joes acknowledgepoux ets of resistance. 'Many physic apswire consion: memselves grounded in Western srience will see mindiumeschased programs for mental death discreters as being somewhat foldsher dielativity impotent in tout ing montald solders, esponally severe or estmesaid. Instaction of the stock of the

#### Why the Growing Trend?


According to specent, work, 79% of medicalisations offer some element of minabul ress training, noted curiment gator Eavie Black, PLO MPH, director of the Anterican



Journal of the American Medical Association, 314(13), 1327-1329 (October 6, 2015)









# Pain and Centrally Sensitized Chronic Pain

# Not all pain is the same: The pathophysiology of painful diseases





dhss.delaware.gov/dsamh/files/2007**gallagher**ii.pps


## **Nociceptive Pain**




Understanding Pain and Pain Amplification. Robert Benett, MD. http://www.myalgia.com/Pain\_amplification/Overview.htm









- serotonergic from nucleus raphe magnus
- adrenergic from locus coeruleus
- dopaminergic from ventral tegmental area and hypothalamus




# A. Antidepressants (e.g. amitriptyline, duloxetine) reduce pain by increasing descending pain inhibition from catecholamines




# *B.* <u>Anti-epileptics</u> (e.g. gabapentin, pregabalin) reduce pain by <u>limiting release of glutamate from afferent peripheral C fiber</u>






# C. <u>Opioids (e.g. morphine) block pain by activating opioid</u> <u>receptors and inhibiting substance P</u>

Blackburn-Munro, G. & Blackburn-Munro, R.E. (2001). Chronic Pain, Chronic Stress and Depression: Coincidence or Consequence? Journal of Neuroendocrinology. Volume 13 (12), 1009-1023. Springer



# STRESS OF CHRONIC PAIN CAUSES CENTRAL SENSITIZATION AND DEPRESSION - I


- Inflammation / nerve injury stimulate nociceptive information to dorsal horn
- · Ascends to brainstem, gated in thalamus



# STRESS OF CHRONIC PAIN CAUSES CENTRAL SENSITIZATION AND DEPRESSION - II

- Inflammation / nerve injury stimulate nociceptive information to dorsal horn
- Ascends to brainstem, gated in thalamus
- Cognitive appraisal in SI cortex
- Acute pain increases arousal via sympathetic and GC routes (excitatory reciprocal link between somatosensory and limbic cortices)

• This is the stress pathway




# STRESS OF CHRONIC PAIN CAUSES CENTRAL SENSITIZATION AND DEPRESSION - III

- Inflammation / nerve injury stimulate nociceptive information to dorsal horn
- Ascends to brainstem, gated in thalamus
- Cognitive appraisal in SI cortex
- Acute pain increases arousal via sympathetic and GC routes (excitatory reciprocal link between somatosensory and limbic cortices)
  - This is the stress pathway
  - →Descending pain modulation PAIN ENDS


# STRESS RESPONSE:

- CRH and/or AVP released
   → anterior pituitary gland
- Stimulates ACTH release
  - $\rightarrow$  adrenal cortex
  - → triggers release of glucocorticoid and proinflammatory cytokines (e.g. IL-1β) release




# **STRESS RESPONSE NEGATIVE FEEDBACK: I**


- Glucocorticoid → negative feedback via GR of HC, PVN, P, and AC
  - $\downarrow$  CRH, AVP release
  - $\downarrow$  ACTH release
  - $\downarrow$  GC
  - $\downarrow$  IL-1 $\beta$



# **STRESS RESPONSE NEGATIVE FEEDBACK: II**

- Glucocorticoid → negative feedback via GR of HC, PVN, P, and AC
  - $\downarrow$  CRH, AVP release
  - $\downarrow$  ACTH release
  - $\downarrow$  GC
  - $\downarrow$  IL-1 $\beta$
- Mineralocorticoid → negative feedback via GR in HC
  - $\uparrow$  Glu  $\rightarrow$  GABA
- Brainstem 5-HT/NE release
- Amy
- P
- neurokinin SP






# STRESS OF CHRONIC PAIN CAUSES CENTRAL SENSITIZATION AND DEPRESSION - III

- Inflammation / nerve injury stimulate nociceptive information to dorsal horn
- · Ascends to brainstem, gated in thalamus
- Cognitive appraisal in SI cortex
- Acute pain increases arousal via sympathetic and GC routes (excitatory reciprocal link between somatosensory and limbic cortices)
  - This is the stress pathway
- Descending pain modulation
   PAIN NEVER ENDS

# STRESS RESPONSE


CRH and/or AVP released
 → anterior pituitary gland


Blackburn-Munro, G. & Blackburn-Munro, R.E. (2001). Chronic Pain, Chronic Stress and Depression: Coincidence or Consequence? Journal of Neuroendocrinology. Volume 13 (12), 1009-1023. Springer



# STRESS RESPONSE DRIVEN BY CHRONIC PAIN

- CRH and/or AVP released
   → anterior pituitary gland
- Stimulates ACTH release
  - $\rightarrow$  adrenal cortex
  - → triggers release of glucocorticoid and proinflammatory cytokines (e.g. IL-1β) release





# STRESS OF CHRONIC PAIN CAUSES CENTRAL SENSITIZATION AND DEPRESSION

- Pain never ends (←PTSD)→
- Chronic Stress  $\rightarrow$
- 'HPA overdrive' →
- Loss of GC inhibition of pro-inflammatory cytokines
  - Proliferation of peripheral inflammation Heightened pain
  - Disinhibition of descending cortical pain modulation ('nociceptive braking')
  - Depletion of catecholaimes (nor)adrenealin from locus coeruleus and dopamine from hypothalamus
    - Depressed behavior and mood (fatigue, insomnia)

<u>Depression is an expression of chronic stress</u> Rodents show stress in their behavior; humans show stress in their behavior and mood

• Chronically stressed rodents have a profile strikingly similar to depressed people

- Depressed people are stressed
- However, not all stressed people are depressed
- The difference between stress and depression in people appears to be cortisol: when high, depression is expressed; when low, stress is the phenotype

Chronic stress (rodents)	Clinical depression (humans)
个CRH/CRH mRNA	个CRH/CRH mRNA
↓CRH receptor affinity/number	↓ CRH receptor affinity/number
个AVP/AVP mRNA	个AVP/AVP mRNA
个CSF levels of CRH/AVP	个CSF levels of CRH/AVP
个Co-expression of CRH/AVP	个Co-expression of CRH/AVP
↓GR/MR number/function	↓GR/MR number/function
Altered plasma ACTH concentration	Altered plasma ACTH concentration
Altered circadian rhythmicity	Altered circadian rhythmicity
Adrenal supersensitivity to ACTH	Adrenal supersensitivity to ACTH
个Corticosterone	↑Cortisol (*cortisol is ↓ in PTSD)
↓ Negative feedback	↓ Negative feedback
Adrenal hypertrophy	Adrenal hypertrophy
Pituitary hypertrophy	Pituitary hypertrophy
Exaggerated corticosterone response	Exaggerated cortisol response
Cognitive deficit	Cognitive deficit
Behavioral disturbance	Behavioral and mood disturbance
Blackburn-Monro & Blackburn-Monro (20	11)


Blackburn-Monro & Blackburn-Monro (2011).

## Pain and PTSD are inter-related

Moeller-Bertram, Tobias, Irina A. Strigo, Alan N. Simmons, Jan M. Schilling, Piyush Patel, and Dewleen G. Baker. "Evidence for acute central sensitization to prolonged experimental pain in posttraumatic stress disorder." *Pain Medicine* 15, no. 5 (2014): 762-771


Scioli-Salter, E. R., Forman, D. E., Otis, J. D., Gregor, K., Valovski, I., & Rasmusson, A. M. (2015). The shared neuroanatomy and neurobiology of comorbid chronic pain and PTSD: Therapeutic implications. *The Clinical journal of pain*, *31*(4), 363-374.

# There Are Many Painful Diseases and Pain Diseases



Rollin Gallagher, MD, MPH, dhss.delaware.gov/dsamh/files/2007gallagherii.pps

### Chronification to Maldynia: The Chronic Pain Cycle (Gallagher, Pain Med 2011)




# Research on ASR and Chronic Pain

'The Health Pathway'


# Autonomic Balance •ASR→Coherence


<u>Central Pain</u> <u>Sensitization</u> •Stress, Depression






- Grant, J. A., & Rainville, P. (2009). Pain sensitivity and analgesic effects of mindful states in Zen meditators: a cross-sectional study. *Psychosomatic Medicine*, 71(1), 106-114.
- McCracken, L. M., Gauntlett-Gilbert, J., & Vowles, K. E. (2007). The role of mindfulness in a contextual cognitive-behavioral analysis of chronic pain-related suffering and disability. *Pain*, *131*(1),63-69.
- Zeidan, F., Gordon, N. S., Merchant, J., & Goolkasian, P. (2010). The effects of brief mindfulness meditation training on experimentally induced pain. *The Journal of Pain*, *11*(3), 199-209.
- Zeidan, F., Grant, J. A., Brown, C. A., McHaffie, J. G., & Coghill, R. C. (2012). Mindfulness meditation-related pain relief: evidence for unique brain mechanisms in the regulation of pain. *Neuroscience letters*, *520*(2), 165-173.





## Fig. 1. HRV Biofeedback reduces effects of chronic pain



Chronic pain causes central sensitization and loss of negative feedback regulation of the stress response, leading to autonomic imbalance, allostatic stress, and depressed mood (Disease Pathway). When autonomic balance is restored, stress is reduced and emotional regulation is recovered (Health Pathway).

#### PILOT STUDY

### Non-pharmacological Intervention for Chronic Pain in Veterans: A Pilot Study of Heart Rate Variability Biofeedback

Melanie E. Berry, MS, United States; Iva T. Chapple, MD, United States; Jay P. Ginsberg, PhD, United States; Kurt J. Gleichauf, PhD, United States; Jeff A. Meyer, PhD, United States; Madan L. Nagpal, PhD, United States

#### Author Affiliations ABSTRACT

Wm. Jennings Bryan Dorn VA Medical Center, Columbia, South Carolina.

#### Correspondence

Jay P. Ginsberg, PhD Jay.Ginsberg@va.gov

Citation Global Adv Health Med. 2014;3(2):28-33. DOI: 10.7453/gahmj.2013.075

#### Key Words

Coherence, heart rate variability (HRV), HRV coherence biofeedback (HRVCB); chronic pain, non-pharmacological intervention

Disclosure The authors completed the IQMJE Form for Disclosure of Potential Conflicts of Interest and had no conflicts to disclose. **Objective:** Chronic pain is an emotionally and physically debilitating form of pain that activates the body's stress response and over time can result in lowered heart rate variability (HRV) power, which is associated with reduced resiliency and lower self-regulatory capacity. This pilot project was intended to determine the effectiveness of HRV coherence biofeedback (HRVCB) as a pain and stress management intervention for veterans with chronic pain and to estimate the effect sizes. It was hypothesized that HRVCB will increase parasympathetic activity resulting in higher HRV coherence measured as power and decrease self-reported pain symptoms in chronic pain patients.

**Study Design:** Fourteen veterans receiving treatment for chronic pain were enrolled in the pre-post intervention study. They were randomly assigned, with 8 subjects enrolled in the treatment group and 6 in the control group. The treatment group received biofeedback intervention plus standard care, and the other group received standard care only. The treatment group received four HRVCB training sessions as the intervention.

Measures: Pre-post measurements of HRV amplitude, HRV power spectrum variables, cardiac coherence, and self-ratings of perceived pain, stress, negative emotions, and physical activity limitation were made for both treatment and control groups.

**Results:** The mean pain severity for all subjects at baseline, using the self-scored Brief Pain Inventory (BPI), was 26.71 (SD=4.46; range=21-35) indicating a moderate to severe perceived pain level across the study subjects. There was no significant difference between the treatment and control groups at baseline on any of the measures. Post-HRVCB, the treatment group was significantly higher on coherence (P=.01) and lower (P=.02) on pain ratings than the control group. The treatment group showed marked and statistically significant (1-tailed) increases over the baseline in coherence ratio (191%, P=.04) and marked, significant (1-tailed) reduction in pain ratings (36%, P<.001), stress perception (16%, P=.02), negative emotions (49%, P<.001), and physical activity limitation (42%, P<.001). Significant between-group effects on all measures were found when pre-training values were used as covariates.

**Conclusions:** HRVCB intervention was effective in increasing HRV coherence measured as power in the upper range of the LF band and reduced perceived pain, stress, negative emotions, and physical activity limitation in veterans suffering from chronic pain. HRVCB shows promise as an effective non-pharmacological intervention to support standard treatments for chronic pain. The pre- treatment values for control and treatment groups were not statistically different for self-ratings of pain, negative emotion, physical activity limitation, or stress.

#### Table 1 Demographics


	Control	Treatment
	n (%)	n (%)
Total	6 (43)	8 (57)
Male	6 (100)	7 (88)
	Mean (SD)	Mean (SD)
Age (y)	44.8 (7.4)	44.5 (6.6)


95% CL of Variable difference Control Treatment t-value<sup>a</sup> P<sup>b</sup> Coherence Pre 0.12 (0.07) 0.22 (0.19) -1.2 .24 (-0.3, 0.8) 0.15 (0.09) Coherence Post 0.42 (0.24) -2.6.02 (-0.5, -0.1) 26.2 (4.2) 27.1 (4.9) -0.4.70 (-6.4, 4.5) Pain\_Pre 17.3 (4.6) 24.3 (6.9) 23 (0.4, 13.8)Pain Post .04 24.8 (6.8) 24.4 (5.8) .90 (-6.8.7.8) Stress Pre 0.1 26.0 (6.9) 20.4 (6.1) .14 (-1.9, 13.2) Stress Post 1.6 Neg\_Emotion\_Pre 30.2 (9.7) 35.0 (3.5) -1.2.28 (-15.0, 5.3) Neg\_Emotion\_Post 25.7 (12.7) 19.8 (10.4) 1.0 .36 (-7.5, 19.4) Activ Red Pre 30.7 (7.1) 34.1 (4.6) -1.1 .30 (-10.2, 3.3) Activ Red Post 26.7 (11.6) 19.9 (10.4) 12 .26 (-6.1, 19.7)

Table 2 Pre- and Post-training Measures for Both Groups, Mean (SD)

<sup>a</sup> Independent t-test, 12 df, all variances equal except Neg\_Emotion\_Pre.
<sup>b</sup> 2-tail.

Abbreviations: Activ\_Red, activity reduction; O, confidence interval; Neg\_Emotion, negative emotion. Figure 4. Changes in HRV Coherence and their associated effect on measures of pain, physical activity, negative emotion, and perceived stress in Veterans with chronic pain who received HRV-B + standard care (green lines) vs only standard care (red lines).





Treatment effects were analyzed with ANCOVA of post scores by group, using pre scores as the covariate.

# Post-HRVB training, the treatment group was significantly lower than the control group on all outcome measures (all p's <0.05).

Table 3 Pre-Post Changes of Measures in the Active HRVCB Treatment Group, Mean (SD)							
Variable	Рте	Post	% Change	Corr_Coeff (P)	t-value <sup>b</sup>	P	95% Cl of difference
Coherence	0.22 (0.19)	0.42 (0.24)	191	-0.05 (0.45)	-1.8	.05	(-0.5, 0.0)
Pain	27.1 (4.9)	17.3 (4.6)	-36	0.52 (0.09)	6.0	<001	(6.0, 13.7)
Stress	24.4 (5.8)	20.4 (6.1)	-16	0.70 (0.03)	2.5	.02	(0.2, 7.84)
Neg_Emotion	35.0 (3.5)	19.8 (10.4)	-49	0.53 (0.08)	4.8	<001	(7.7, 22.8)
Activ_Red	34.1 (4.6)	19.9 (10.4)	-42	0.22 (0.30)	3.9	<001	(-16.0, -7.72)

<sup>2</sup> 1-tell.

<sup>b</sup> dependent t-test, df 7.

Abbreviations: Activ\_Red, activity reduction; CI, confidence interval; Corr Coeff, correlation coefficient; Neg\_Emotion, negative emotion.





GREENVILLE HEALTH SYSTEM

Cancer Institute

Center for Integrative Oncology & Survivorship







# Use of Heart Rate Variability (HRV) Biofeedback for Symptom Management among Cancer Survivors

Mark A. O'Rourke, MD, Medical Director Center for Integrative Oncology and Survivorship Greenville Health System Cancer Institute Greenville, South Carolina **Investigators and Staff Greenville Health System**  Mark A. O'Rourke, MD, co-PI •Regina Franco, MSN, ANP-C Kerri Susko, MSW, LISW-CP •William M. Hendry, DOM, L.Ac. Elizabeth Crowley, Ph.D, RN, LMSW •Sherry A. Stokes, M.S. •W. Larry Gluck, M.D. •Katie Daniels, BS University of South Carolina •James Burch, MS, Ph.D, co-Pl •J.P. Ginsberg, Ph.D. •Jameson Sofge, MS •James Hébert, MSPH, ScD

## Background:


Cancer survivors have lower HRV coherence than normal controls and HRVB training improves HRV coherence, restores autonomic health

## **Research Question:**

Will HRVB reduce late effects of cancer and its treatment, including stress, depression, fatigue, pain, and insomnia?

## Method:

Randomized, waitlist controlled, clinical trial. Participants in the intervention arm receive weekly HRV-B training up to six weeks; a wait-list control group was matched to the intervention arm. Outcome measures were assessed at baseline (pre) and after week six (post)



Symptom Cluster Questionnaires

- Socio-demographic inventory
- Brief Pain Inventory (BPI)
- <u>Perceived Stress Scale (PSS)</u>
- Beck Depression Inventory–II (BDI-II0
- Suscro Distress Inventory
- <u>Multidimensional Fatigue Inventory (MFI,</u> <u>short form)</u>
- Insomnia Symptom Questionnaire
- Posttraumatic Stress Disorder Checklist Civilian Form
- Munich Chronotype Questionnaire

Status	Total
Screened	179
Ineligible	117
Enrolled	38
Dropped Out	4
Completed	34

		Group B	
	Group A	(N=17)	two-
	(N=17)	Wait List	tailed p-
	HRVB	Control	value
Age (years), mean ± stderr	60.0 ± 2.5	58.9 ± 2.5	0.7621
Sex, count(%)			0.0445
Male	5 (29.4)	0 (0)	
Female	12 (70.6)	17 (100)	
Ethnic Group, count (%)			0.6012
Hispanic or Latino	1 (5.9)	0 (0)	
Not Hispanic or Latino	15 (88.2)	14 (82.3)	
Refuse/Don't			
Know/Missing	1 (5.9)	3 (17.7)	
Race, count (%)			0.349
White	14 (82.3)	13 (76.4)	
Black or African American	1 (5.9)	2 (11.8)	
Other	2 (11.8)	0 (0)	
Refused/Don't			
Know/Missing	0 (0)	2 (11.8)	
Education (years), mean ±			
stderr			0.9279
High School	4 (23.5)	4 (23.5)	
College	7 (41.1)	6 (35.3)	
Graduate School	3 (17.7)	5 (29.4)	
Missing	3 (17.7)	2 (11.8)	
Income <i>,</i> count (%)			0.7665
Under \$50,000	6 (35.3)	5 (29.4)	
\$50,000-\$100,000	4 (23.5)	5 (29.4)	
\$100,000 or more	6 (35.3)	4 (23.5)	
Refuse/Don't			
Know/Missing	1 (5.9)	3 (17.7)	

WE ASKED ALL THE QUESTIONS OF THE PRELIMINARY DATA WE CAN, USING STRICT AND RIGOROUS STATISTICAL ANALYSIS

Means	Means (SE) and Significance of Differences of Outcome Variables				Outcome		
		Variable					
Intention to Treat Completers (n's and means vary from tabled values)							
Group	Pre-1	Post- <sup>2</sup>	LMM <sup>3</sup>	Pre- Post <sup>4</sup>	ANCOVA <sup>5</sup>		
HRVB 0.37(0.0) <sup>ns</sup> 0.84(0.3) <sup>*u</sup> *							
<b>Control</b> 0.40(0.0) 0.33(0.0) ns *							
SDNN							
HRVB	20.5(1.7) <sup>ns</sup>	35.0(7.6)*u	*	*	*		
Control	18.9(2.7)	17.6(1.4)		ns			
RMSSD							
HRVB	17.1(1.7) <sup>ns</sup>	25.4(4.2) <sup>*</sup> "	ns	*	nc		
Control 15.9(2.7) 15.7(1.8) ns ns							
* <u>&lt;</u> .05, ** <u>&lt;</u> .01,*** <u>&lt;</u> .005; <sup>1</sup> Independent t-test, 2-t, HRVB							
vs Control; <sup>2</sup> Independent t-test, 1-t, HRVB vs Control;							
-	-	<sup>1</sup> Dependent t-	-	-			
	fect ; "Uneq	ual variance; L	.MM=L	inear N	/lixed		
Model;							

Means	Means (SE) and Significance of Differences of Outcome Variables				Outcome		
		Variable					
Intention to Treat Completers (n's and means vary from tabled values)							
Group	Pre-1	Post- <sup>2</sup>	LMM <sup>3</sup>	Pre- Post <sup>4</sup>	ANCOVA⁵		
STRESS							
HRVB 17.2(2.0) <sup>ns</sup> 11.4(1.7) * ***							
Control         19.0(1.6)         17.2(1.6)         **         *							
DEPRESSION							
HRVB	13.1(3.0) <sup>ns</sup>	5.5(2.5)**	***	***	*		
Control	17.1(1.6)	13.6(2.2)		ns			
DISTRESS							
HRVB	14.2(3.0) <sup>ns</sup>	9.7(2.3)***	**	**	*		
<b>Control</b> 20.6(1.8) 18.5(2.1) ns							
* <u>&lt;</u> .05, ** <u>&lt;</u> .01,*** <u>&lt;</u> .005; <sup>1</sup> Independent t-test, 2-t, HRVB							
vs Control; <sup>2</sup> Independent t-test, 1-t, HRVB vs Control;							
-	<sup>3</sup> GroupxPre-Post ix; <sup>4</sup> Dependent t-test, 1-t; <sup>5</sup> Between						
group ef	fect ; "Uneq	ual variance; L	.MM=L	inear N	/lixed		
Model;							

Variable Intention to Treat Completers (n's and means vary from tabled values)	Means	Means (SE) and Significance of Differences of Outcome						
Intention to TreatCompleters (n's and means vary from tabled values)GroupPre-1Post-2LMM³Pre- Post4FATIGUE-GENERALPost4Post4ANCOVA5HRVB12.4(1.0)ns10.0(1.1)******14.8(0.8)14.0(0.8)nsnsFATIGUE-MENTALHRVB11.3(1.3)ns9.5(1.2)*nsNSnsnsns			Variables					
and means vary from tabled values)         Group       Pre-1       Post-2       LMM <sup>3</sup> Pre- ANCOVA <sup>5</sup> FATIGUE-GENERAL       Post <sup>4</sup> Post <sup>4</sup> NCOVA <sup>5</sup> HRVB       12.4(1.0) <sup>ns</sup> 10.0(1.1)***       **       *         Control       14.8(0.8)       14.0(0.8)       ns       ns         FATIGUE-MENTAL       HRVB       11.3(1.3) <sup>ns</sup> 9.5(1.2)*       ns       ns		· · ·						
Group       Pre-1       Post-2       LMM3       Pre-Post4       ANCOVA5         FATIGUE-GENERAL       Post4       Post4       Post4       NCOVA5         HRVB       12.4(1.0)ns       10.0(1.1)***       **       *       ns         Control       14.8(0.8)       14.0(0.8)       ns       ns       ns         HRVB       11.3(1.3)ns       9.5(1.2)*       ns       ns       ns								
$\begin{tabular}{ c c c c c c c } \hline & & & & & & & & & & & & & & & & & & $								
Group         Pre-1         Post-2         LMM3         Pre- Post4         ANCOVA5           FATIGUE-GENERAL         HRVB         12.4(1.0) <sup>ns</sup> 10.0(1.1)***         **         *         ns           Control         14.8(0.8)         14.0(0.8)         **         ns         ns           FATIGUE-MENTAL         HRVB         11.3(1.3) <sup>ns</sup> 9.5(1.2)*         ns         ns					from	tabled		
FATIGUE-GENERAL           HRVB         12.4(1.0) <sup>ns</sup> 10.0(1.1)***         *         *         ns           Control         14.8(0.8)         14.0(0.8)         ns         ns           FATIGUE-MENTAL         HRVB         11.3(1.3) <sup>ns</sup> 9.5(1.2)*         ns         ns					va	lues)		
FATIGUE-GENERAL         HRVB       12.4(1.0) <sup>ns</sup> 10.0(1.1)***       *       *       *       ns         Control       14.8(0.8)       14.0(0.8)       ns       ns       ns         FATIGUE-MENTAL       HRVB       11.3(1.3) <sup>ns</sup> 9.5(1.2)*       ns       ns	Group	Pre-1	Post- <sup>2</sup>	LMM <sup>3</sup>	Pre-	ANCOVA <sup>5</sup>		
HRVB         12.4(1.0) <sup>ns</sup> 10.0(1.1)***         **         *         ns           Control         14.8(0.8)         14.0(0.8)         ns         ns           FATIGUE-MENTAL         HRVB         11.3(1.3) <sup>ns</sup> 9.5(1.2)*         ns         ns					Post <sup>4</sup>			
HRVB       12.4(1.0) <sup>M</sup> 10.0(1.1) <sup>M</sup> **       ns         Control       14.8(0.8)       14.0(0.8)       **       ns         FATIGUE-MENTAL         HRVB       11.3(1.3) <sup>ns</sup> 9.5(1.2)*       ns       ns	FATIGUE-GENERAL							
Control         14.8(0.8)         14.0(0.8)         ns           FATIGUE-MENTAL         HRVB         11.3(1.3) <sup>ns</sup> 9.5(1.2)*         ns         ns	HRVB	12.4(1.0) <sup>ns</sup>	10.0(1.1)***	**	*	nc		
HRVB 11.3(1.3) <sup>ns</sup> 9.5(1.2)* ns ns	Control 14.8(0.8) 14.0(0.8) ns							
	FATIGUE-MENTAL							
Control 13.7(1.1) 13.1(1.1) 13 ns	HRVB	11.3(1.3) <sup>ns</sup>	9.5(1.2)*	20	ns	200		
	Control	13.7(1.1)	13.1(1.1)	115	ns	115		
FATIGUE-REDUCED ACTIVITY								
HRVB 9.3(1.1) <sup>ns</sup> 6.4(0.8)* *	HRVB	9.3(1.1) <sup>ns</sup>	6.4(0.8)*	**	*	nc		
<b>Control</b> 10.9(1.0) 9.3(1.0) ** ns								
* <u>&lt;</u> .05, ** <u>&lt;</u> .01,*** <u>&lt;</u> .005; <sup>1</sup> Independent t-test, 2-t, HRVB								
vs Control; <sup>2</sup> Independent t-test, 1-t, HRVB vs Control;	ntrol;							
<sup>3</sup> GroupxPre-Post ix; <sup>4</sup> Dependent t-test, 1-t; <sup>5</sup> Between	<sup>3</sup> Groupx	Pre-Post ix; <sup>4</sup>	<sup>1</sup> Dependent t-	test, 1	-t; ⁵Betv	ween		
group effect ; "Unequal variance; LMM=Linear Mixed	group ef	fect ; "Uneq	ual variance; L	.MM=L	.inear N	/lixed		
Model;	Model;							

Means	Means (SE) and Significance of Differences of Outcome						
		Variables					
-	Variable						
	Intention to Treat Completers (n's and means vary						
	from tabled values)						
Group	Pre-1	Post- <sup>2</sup>	LMM <sup>3</sup>	Pre-	ANCOVA <sup>5</sup>		
				Post <sup>4</sup>			
PAIN SEVERITY							
HRVB 2.7(0.6) <sup>ns</sup> 1.9(0.5) <sup>ns</sup> ns							
Control         2.5(0.5)         2.7(0.6)         ns         ns							
PAIN INTERFERENCE							
HRVB	2.4(0.8) <sup>ns</sup>	1.4(0.4)* <sup>u</sup>	nc	ns	nc		
Control         3.4(0.6)         3.1(0.7)         ns         ns							
* <u>&lt;</u> .05, ** <u>&lt;</u> .01,*** <u>&lt;</u> .005; <sup>1</sup> Independent t-test, 2-t, HRVB					, HRVB		
vs Control; <sup>2</sup> Independent t-test, 1-t, HRVB vs Control;							
<sup>3</sup> Groupx	<sup>3</sup> GroupxPre-Post ix; <sup>4</sup> Dependent t-test, 1-t; <sup>5</sup> Between						
group ef	fect ; "Uneq	ual variance; I	LMM=L	.inear N	/lixed		
Model;							

Means (SE) and Significance of Differences of Outcome Variables							
		Variable					
Intention to Treat Completers (n's							
				and m	eans vary		
	from tabled						
	values)						
Group	Pre-1	Post- <sup>2</sup>	LMM <sup>3</sup>	_	ANCOVA <sup>5</sup>		
Post <sup>4</sup>							
SLEEP SYMPTOMS							
HRVB 14.7(1.5) <sup>ns</sup> 8.1(1.7)*** <sup>u</sup> *** ***							
<b>Control</b> 16.5(1.3) 18.3(0.8) ns							
SLEEP-DAYTIME IMPAIRMENT							
HRVB	10.7(1.8) <sup>ns</sup>	5.4(2.0)**	**	***	***		
<b>Control</b> 12.3(1.7) 13.0(1.8) ns							
*<.05, **<.01,***<.005; <sup>1</sup> Independent t-test, 2-t, HRVB							
vs Control; <sup>2</sup> Independent t-test, 1-t, HRVB vs Control;							
<sup>3</sup> Groupx	Pre-Post ix; '	<sup>1</sup> Dependent t-	test, 1	-t; ⁵Betv	ween		
group ef	fect ; "Uneq	ual variance; L	.MM=L	.inear N	/lixed		
Model;							

# **PLANNED ANALYSES**

- COVARIATE
- PRINCIPAL COMPONENTS
- HIERARCHICAL REGRESSION?


## **HYPOTHESIS FOR VA MERIT PROPOSAL**

- COHERENCE REDUCES CENTRAL SENSITIZATION OF PAIN, STRESS, AND DEPRESSION
- HRV BIOFEEDBACK PRODUCES COHERENCE
- HRV BIOFEEDBACK WILL REDUCE CENTRALLY SENSITIZED PAIN, STRESS, AND DEPRESSION
- HRVB AND COHERENCE WILL REDUCE CENTRALLY SENSITIZED PAIN AND ASSOCIATED STRESS AND DEPRESSION BECAUSE THE SAME NEURAL STRUCTURES AND CIRCUITS ARE INVOLVED IN BOTH

# HYPOTHESIS COROLLARY

HRVB AND COHERENCE WILL NOT IMPROVE PAIN THAT IS SOLELY
 FROM A NEUROPATHIC SOURCE

PI: Ginsberg, Jay	Title: HRV Biofeedback in Pain Patients	Title: HRV Biofeedback in Pain Patients: Pilot Intervention for Pain, Fatigue & Slee		
Received: 09/08/2014	FOA: CX14-006	Council: 01/2015		
Competition ID:	FOA Title: CSR&D MERIT REVIEW AV	VARD FOR CLINICAL TRIALS		
1 I01 CX001182-01A1	Dual:	Accession Number: 3732973		
IPF: 10018661	Organization: VETERANS HEALTH AD	DMINISTRATION		
Former Number:	Department: Mental Health			
IRG/SRG: CLNA	AIDS: N	Expedited: N		
Subtotal Direct Costs (excludes consortium F&A) Year 1: 198,078 Year 2: 149,913 Year 3: 149,932 Year 4: 149,935	Animals: N Humans: Y Clinical Trial: N Current HS Code: 20 HESC: N	New Investigator: N Early Stage Investigator: N		
Senior/Key Personnel:	Organization:	Role Category:		
Jay Ginsberg Ph.D	WJB Dorn VA Medical Center	PD/PI		
James Burch Ph.D	University of South Carolina	MPI		
Alexander McLain Ph.D	University of South Carolina	Co-Investigator		
Raouf Gharbo Ph.D	Hampton Roads Riverside Regional Medical Center	Consultant		
James Hebert ScD	University of South Carolina	Consultant		
Francis Spinale M.D.	WJB Dorn VA Medical Center	Consultant		
Tarek Sobeih Ph.D	Dorn Research Institute	Other Professional-Recruitment Coordinator		



Number of veterans screened or prescreened: 220 Number of veterans enrolled: 10 Number of veterans completed: 9

